<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The incidence of <z:mp ids='MP_0009308'>adenocarcinomas</z:mp> in <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> has been rising in the last two decades in the United States and Western Europe for yet unknown reasons </plain></SENT>
<SENT sid="1" pm="."><plain>We reported previously a large multi-institutional trial implicating p53 mutations as being involved in the pathogenesis of Barrett's <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> and representing an early marker for the malignant potential of Barrett's epithelium </plain></SENT>
<SENT sid="2" pm="."><plain>A prospective study was performed to evaluate the prognostic impact of p53 mutations on survival in 59 patients with Barrett's <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Tissue for DNA analysis was obtained by endoscopic biopsy or immediately after surgical resections from the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>, Barrett's epithelium, and <z:mpath ids='MPATH_458'>normal</z:mpath> stomach and esophagus </plain></SENT>
<SENT sid="4" pm="."><plain>p53 mutation analysis was performed by PCR-single strand conformational polymorphism screening of exons 5-9 and DNA sequencing to unequivocally prove the presence of a mutation </plain></SENT>
<SENT sid="5" pm="."><plain>p53 mutations were identified in 30 of 59 (50.8%) patients </plain></SENT>
<SENT sid="6" pm="."><plain>The presence of a p53 mutation in the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> had a significant impact on survival after curative resections (RO-resections) with cumulative 5-year survival probabilities of 68.8+/-9.7% for mutation-negative <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> and 24.3+/-9.9% for mutation-positive <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> (log rank: P &lt; 0.001) </plain></SENT>
<SENT sid="7" pm="."><plain>By Cox proportional hazard analysis, including the parameters of gender, age, Union International Contre <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> stage, grading, and p53 mutation status, only Union International Contre <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> stage (P &lt; 0.0001) and p53 mutation status (P &lt; 0.02) were of significant independent prognostic importance </plain></SENT>
<SENT sid="8" pm="."><plain>p53 mutation analysis by DNA sequencing is of significant independent prognostic importance next to histopathological <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> stage in patients with curatively resected (RO-resection) Barrett's <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>It appears that p53 mutational status is a valuable parameter to define low-risk (p53 mutation-negative) and high-risk (p53 mutation-positive) groups for treatment failure after curative resections </plain></SENT>
</text></document>